Rondec® Syrup (carbinoxamine maleate and pseudoephedrine hcl) is a sugar-free, alcohol-free, bubblegum-flavored syrup for oral administration for adults and pediatric patients 2 years and older.
Each teaspoonful (5mL) contains:
Chlorpheniramine maleate . . . .
. . . . . . . . . . . 4.0 mg
Phenylephrine hydrochloride . . . . . . . . . . . . 12.5 mg
Inactive ingredients: D&C Red No. 33, Flavor, Glycerin, Propylene Glycol, Purified Water, Sodium Saccharin, Sorbitol.
Chlorpheniramine maleate is an antihistamine with the chemical name: 2-Pyridinepropanamine, γ-(4-chlorophenyl)-N,N-dimethyl-,(Z)-2-butenedioate (1:1). Its chemical structure is as follows:
C16H19ClN2 •C4H4O4 M.W. 390.86
Phenylephrine hydrochloride is a mydriatic and a decongestant with the chemical name: (-)-m-Hydroxy-a-[(methylamino)methyl]benzyl alcohol hydrochloride. Its chemical structure is as follows:
C9H13NO2•HCI M.W. 203.67
Symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis. Rondec® Syrup (carbinoxamine maleate and pseudoephedrine hcl) is an immediate dosage form allowing titration of dose 4-6 times per day.
DOSAGE AND ADMINISTRATION
Adults and Children 12 years of age and older: 1 teaspoonful (5mL) every 4 to 6 hours, not to exceed 6 teaspoonsful in 24 hours. Children 6 to under 12 years of age: 1/2 teaspoonful every 4 to 6 hours, not to exceed 3 teaspoonsful in 24 hours. Children 2 to under 6 years of age: 1/4 teaspoonful every 4 to 6 hours, not to exceed 1.5 teaspoonsful in 24 hours. Not recommended for use in children under 2 years of age.
In mild cases or in particularly sensitive patients, less frequent or reduced doses may be appropriate and adequate.
Rondec® Syrup (carbinoxamine maleate and pseudoephedrine hcl) is a sugar-free, alcohol-free, bubble gum-flavored syrup available in bottles of 16 fluid ounces (473 mL), NDC 68188-061-16; bottles of 4 fluid ounces (118 mL), NDC 68188-061-04; and bottles of 20 mL, NDC 68188-061-20.
Store at Controlled Room Temperature between 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature]. Avoid exposure to heat. Keep tightly closed.
Dispense in USP tight, light-resistant container with child resistant closure.
KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.
Manufactured for: Alliant Pharmaceuticals, Inc., Alpharetta, GA 30022 USA. Rev. 09/05.
Antihistamines may cause sedation, dizziness, diplopia, vomiting, diarrhea, dry mouth, headache, nervousness, nausea, anorexia, heartburn, weakness, polyuria and dysuria and, rarely, excitability in children. Urinary retention may occur in patients with prostatic hypertrophy. Sympathomimetic amines may cause convulsions, CNS stimulation, cardiac arrhythmia, respiratory difficulties, increased heart rate or blood pressure, hallucinations, tremors, nervousness, insomnia, pallor and dysuria.
Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants. MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines. Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamines. Effects of sympathomimetics are increased with MAO inhibitors and beta-adrenergic blockers.
Do not exceed recommended dosage.
Sympathomimetic amines should be used judiciously and sparingly in patients with hypertension, diabetes, ischemic heart disease, hyperthyroidism, increased intraocular pressure or prostatic hypertrophy. (See CONTRAINDICATIONS) Sympathomimetic amines may produce CNS stimulation with convulsions or cardiovascular collapse with accompanying hypotension. The elderly (60 years and older) are more likely to exhibit adverse reactions. Antihistamines may cause excitability, especially in children. At doses higher than the recommended dose, nervousness, dizziness or sleeplessness may occur.
Use in Pregnancy
Pregnancy Category C
Animal reproduction studies have not been conducted with Rondec® Syrup (carbinoxamine maleate and pseudoephedrine hcl) . It is not known whether this product can cause fetal harm when administered to a pregnant woman or affect reproduction capacity. Give to a pregnant woman only if clearly needed.
It is not known whether the drugs in Rondec® Syrup (carbinoxamine maleate and pseudoephedrine hcl) are excreted in human milk. Since many drugs are excreted in human milk and because of the potential for serious side effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue the use of this product, taking into account the importance of the drug to the mother.
No information is available as to specific results of an overdose of Rondec® Syrup (carbinoxamine maleate and pseudoephedrine hcl) . The signs, symptoms and treatment described below are those of H1 antihistamine and ephedrine overdose.
Should antihistamine effects predominate, central action constitutes the greatest danger. In the small child, predominate symptoms are excitation, hallucination, ataxia, incoordination, tremors, flushed face and fever. Convulsions, fixed and dilated pupils, coma and death may occur in severe cases. In the adult, fever and flushing are uncommon; excitement leading to convulsions and postictal depression is often preceded by drowsiness and coma. Respiration is usually not seriously depressed; blood pressure is usually stable.
Should sympathomimetic symptoms predominate, central effects include restlessness, dizziness, tremor, hyperactive reflexes, talkativeness, irritability and insomnia. Cardiovascular and renal effects include difficulty in micturition, headache, flushing, palpitation, cardiac arrhythmia, hypertension with subsequent hypotension and circulatory collapse. Gastrointestinal effects include dry mouth, metallic taste, anorexia, nausea, vomiting, diarrhea and abdominal cramps.
(a) Evacuate stomach as condition warrants. Activated charcoal may be useful. (b) Maintain a nonstimulating environment. (c) Monitor cardiovascular status. (d) Do not give stimulants. (e) Reduce fever with cool sponging. (f) Use sedatives or anticonvulsants to control CNS excitation and convulsions. (g) Physostigmine may reverse anticholinergic symptoms. (h) Ammonium chloride may acidify the urine to increase urinary excretion of phenylephrine. (i) Further care is symptomatic and supportive.
Patients with hypersensitivity or idiosyncrasy to any of its ingredients. Sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and patients on monoamine oxidase (MAO) inhibitor therapy. Antihistamines are contraindicated in patients with narrow angle glaucoma, urinary retention, peptic ulcer, and during an asthma attack.
Antihistaminic and decongestant actions
Chlorpheniramine maleate possesses H1 antihistaminic activity and mild anticholinergic and sedative effects. Peak plasma concentration is reached in 5 hours. Urinary excretion is the major route of elimination. The liver is assumed to be the major site of metabolic transformation.
Phenylephrine hydrochloride is an oral sympathomimetic amine that acts as a decongestant to respiratory tract mucous membranes. While its vasoconstrictor action is similar to that of ephedrine, phenylephrine has less pressor effect in normotensive adults. Serum half-life for phenylephrine is 6 to 8 hours. Acidic urine is associated with faster elimination of the drug. About one-half of the administered dose is excreted in the urine.
Avoid alcohol and other CNS depressants while taking this product. Patients sensitive to antihistamines may experience moderate to severe drowsiness.Patients sensitive to sympathomimetic amines may notice mild CNS stimulation. Antihistamines may impair mental and physical abilities required for the performance of potentially hazardous tasks such as driving a vehicle or operating machinery. Patients should be warned accordingly.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.